Oculis Holding AG

4 months ago · prnewswire.com

Oculis Holding AG SEC filings continued to describe the OCS-01 DME program as on track for FDA submission after Phase 3 DIAMOND trials had already failed -- shares fell over 23% NEW YORK, June 1, 2026 /PRNewswire/ -- Investors in Oculis Holding AG (NASDAQ: OCS) lost approximately 23.4% of their holdings in a single session after the Company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for lead product OCS-01 failed to meet the primary endpoint in diabetic macular edema and that Oculis would not pursue an FDA filing for the indication. Shareholders who lost money on OCS are encouraged to submit their information to discuss their legal rights.

4 months ago · newsfilecorp.com

New York, New York--(Newsfile Corp. - June 1, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential violations of the federal securities laws. Multiple SEC filings made prior to the stock collapse continued to present the OCS-01 DME program as progressing toward regulatory approval.

4 months ago · marketbeat.com

Oculis NASDAQ: OCS said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug Administration filing for the drug candidate in that indication.

4 months ago · globenewswire.com

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

4 months ago · globenewswire.com

Zug, Sviss, May 29, 2026 (GLOBE NEWSWIRE) -- Aðalviðmiðið (e. primary endpoint) um breytingu á sjónskerpu frá upphafspunkti og fram að viku 52 náðist í hvorugri fasa 3 rannsókninni Önnur viðmið (e. secondary endpoint) um breytingu á þykkt sjónhimnunnar sýndi fram á verulega og varanlega minnkun með OCS-01 miðað við lyfleysu í báðum rannsóknunum Oculis mun beina þróunarstarfi og fjármagni að yfirstandandi PIONEER-skráningaráætluninni á Privosegtor við sjóntaugakvillum og PREDICT-1 skráningarrannsókninni á Licaminlimab við augnþurrki (e.

4 months ago · globenewswire.com

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial and persistent reduction with OCS-01 vs vehicle in both trials Oculis will focus its developmental efforts and financial resources on the ongoing Privosegtor PIONEER registrational program in optic neuropathies and the Licaminlimab PREDICT-1 registrational trial in dry eye disease Financial position remains strong with $278 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing cash runway into 2H 2029 Conference call today at 4:30 pm ET Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema (DME). The DIAMOND (DIAbetic Macular edema patients ON a Drop) program consisted of two Phase 3, double-masked, randomized, multi-center trials to evaluate the efficacy and safety of OCS-01 eye drops in patients with DME following 52 weeks of treatment.

4 months ago · globenewswire.com

ZUG, Switzerland, May 14, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2026 Annual General Meeting held on May 13, 2026 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 12:00 p.m. CEST, including the election of Gregory D. Perry to its Board of Directors.

4 months ago · zacks.com

Oculis Holding AG (OCS) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to a loss of $0.77 per share a year ago.

4 months ago · globenewswire.com

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026 Licaminlimab PREDICT-1 Trial in Active Site Recruitment Phase, Pioneering a Genotype-Driven Path to Precision Medicine in Dry Eye Disease Privosegtor Regulatory Path Cleared via FDA SPA; PIONEER-1 Phase 3 Trial Advances with Ongoing Site Activation Cash, cash equivalents, and short-term investments of $277.6 million as of March 31, 2026, providing cash runway into 2H 2029 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the first quarter ended March 31, 2026, and provided an overview of the Company's progress. Riad Sherif, M.D.

5 months ago · globenewswire.com

ZUG, Switzerland, May 7 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of optic neuritis (ON). This formal FDA agreement confirms the design and planned analysis of the PIONEER-1 study are adequate to address the objectives necessary to support a future NDA submission, subject to a successful trial outcome and FDA review of the complete submission.